title: Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
abstract: The period between isolation of HIV in the early 1980s and the development of effective viral inactivation procedures able to eradicate the virus from the blood supply was long and unfortunately many recipients of blood-derived products became infected; this translated into a devastating impact on their quality of life, quality of care as well as on their life expectancy. Some years later, hepatitis C virus infection was identified as another known blood-borne disease complicating the treatment of haemophilia. Nowadays, the potential threat of emerging new pathogens has stressed the need to provide effective but primarily safe products with regard to infectious agents, as well as to regularly update therapeutic guidelines for haemophilia. The aim of the present publication was to review some of the crucial aspects related to the choice of haemostatic concentrates for the treatment of haemophilia and other inherited bleeding disorders, to analyse the current situation in the United States, Canada and European Union countries and to report the most relevant aspects of the Spanish consensus opinion of haemophilia-treating doctors for the use of therapeutic products for haemophilia recently issued. Essentially, it suggests that a gradual switch to recombinant concentrates may be a beneficial decision for patients with haemophilia and for the National Health Service.
authors.affiliation: Scientific Committee, Royal Foundation Victoria Eugenia, Madrid, Spain. jbattle@canalejo.org
authors.forename: Javier
authors.initials: J
authors.lastname: Batlle
authors.forename: Ana
authors.initials: A
authors.lastname: Villar
authors.forename: Antonio
authors.initials: A
authors.lastname: Liras
authors.forename: Concepción
authors.initials: C
authors.lastname: Alonso
authors.forename: Carmen
authors.initials: C
authors.lastname: Altisent
authors.forename: Dilia
authors.initials: D
authors.lastname: Brito
authors.forename: Manuel
authors.initials: M
authors.lastname: Moreno
authors.forename: Félix
authors.initials: F
authors.lastname: Lucía
authors.forename: Carmen
authors.initials: C
authors.lastname: Sedano
authors.forename: Manuel
authors.initials: M
authors.lastname: Prieto
authors.forename: Natividad
authors.initials: N
authors.lastname: Calvente
authors.forename: José A
authors.initials: JA
authors.lastname: Aznar
authors.forename: Víctor
authors.initials: V
authors.lastname: Jiménez
authors.forename: Vicente
authors.initials: V
authors.lastname: Soriano
authors.forename: Javier R
authors.initials: JR
authors.lastname: Martorell
authors.forename: Gemma
authors.initials: G
authors.lastname: Iruín
authors.forename: Juan M
authors.initials: JM
authors.lastname: Bergua
authors.forename: Carlos
authors.initials: C
authors.lastname: Aguilar
mesh_terms: D016913:Blood Component Transfusion; D017848:Blood-Borne Pathogens; D006678:HIV; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006467:Hemophilia A / Q000628:therapy*; D006526:Hepatitis C / Q000517:prevention & control* / Q000635:transmission; D017410:Practice Guidelines as Topic; D011787:Quality of Health Care; D011788:Quality of Life; D013030:Spain; D038301:Virus Inactivation